Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
03 5월 2023 - 9:00PM
Business Wire
Leading Cardiothoracic Surgeon Joins Leadership Team as the
Company Leverages its Proprietary nsPFA™ Technology for the
Treatment of Atrial Fibrillation
Pulse Biosciences, Inc. (Nasdaq: PLSE), Pulse Biosciences, Inc.
(Nasdaq: PLSE), a company leveraging its novel and proprietary
nanosecond pulsed field ablation (nsPFA™) technology for the
treatment of atrial fibrillation, today announced the appointment
of Gansevoort “Gan” Dunnington, M.D. as its Chief Medical
Officer.
“On behalf of the Company, I am thrilled to welcome Dr.
Dunnington to the Pulse Biosciences team,” said Kevin Danahy, Chief
Executive Officer of Pulse Biosciences. “Dr. Dunnington brings a
wealth of knowledge, expertise, and experience in the field of
cardiothoracic surgery, where he is a leader in pioneering novel
less-invasive technologies that improve the lives of patients with
atrial fibrillation. We look forward to his leadership and
contributions, as we continue to harness the power of nanosecond
pulsed field ablation to have a significant and meaningful positive
impact on the treatment outcomes of atrial fibrillation, all the
while being increasingly patient and physician friendly.”
Dr. Dunnington is a cardiothoracic surgeon and the Director of
Cardiothoracic Surgery at St. Helena Hospital (Napa Valley). He
specializes in minimally invasive complex cardiothoracic procedures
including the Hybrid Cox-Maze procedure for the treatment of atrial
fibrillation (AF). Prior to his time at St. Helena Hospital, Dr.
Dunnington was an assistant professor at Stanford University and
assistant director of cardiothoracic surgery at El Camino Hospital,
a Stanford University affiliate. Dr. Dunnington obtained his
medical degree from the Medical College of Virginia. He completed
his residency at Stanford University, where he served as Chief
Resident of Surgery, and completed a fellowship in cardiothoracic
surgery at the University of Virginia.
“I believe nsPFA can meaningfully advance the treatment of AF
for patients,” said Dr. Dunnington. “Based on my experience using
this technology in preclinical studies, I believe the
differentiated mechanism of action has the potential to
significantly improve the safety and efficacy profile of cardiac
ablation procedures and to disrupt the AF surgical device market. I
am excited to join the Pulse Biosciences team at this important
stage of the product and look forward to helping to bring this
novel and uniquely differentiated technology to patients and
healthcare providers around the world.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation as well as a select few other
opportunities currently served by alternative established ablation
procedures. Visit pulsebiosciences.com to learn more.
Pulse Biosciences, CellFX, Nano-pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to statements concerning the effectiveness of
the Company’s nsPFA technology and CellFX System to non-thermally
clear cells while sparing adjacent non-cellular tissue, statements
concerning the Company’s expected product development efforts,
statements concerning customer adoption and future use of the
CellFX System to address a range of conditions such as atrial
fibrillation, and Pulse Biosciences’ expectations, whether stated
or implied, regarding whether the Company’s nsPFA technology will
become a disruptive treatment option for treating cardiac
arrhythmias and whether future clinical studies will show the
CellFX System is safe and effective to treat atrial fibrillation or
any other medical condition, and other future events. These
statements are not historical facts but rather are based on Pulse
Biosciences’ current expectations, estimates, and projections
regarding Pulse Biosciences’ business, operations and other similar
or related factors. Words such as “may,” “will,” “could,” “would,”
“should,” “anticipate,” “predict,” “potential,” “continue,”
“expects,” “intends,” “plans,” “projects,” “believes,” “estimates,”
and other similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences’ filings with the
Securities and Exchange Commission. Pulse Biosciences undertakes no
obligation to revise or update information in this release to
reflect events or circumstances in the future, even if new
information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005371/en/
Investor Contacts: Pulse Biosciences Kevin Danahy, CEO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Pulse Biosciences (NASDAQ:PLSE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024